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INTRODUCTION 
.Prior to 1959 chloramphenicol had been considered 
relatively free from side effects other than those of bone 
marrow depression (1) and bacterial or fungal superinfection. 
(2) The concern regarding the increasing incidence of 
nursery infections had resulted in widespread use of anti-
biotics for prophylaxis as well as therapy.(3t4) Chloram-
phenicol gained popularity in this field because of its 
greater effectiveness against those bacterial agents which 
more commonly cause trouble in the premature nursery, i.e. 
staphylococci and gram negative rods as well as strepto-
cocci and pneumococci. However, prior to the Parke, Davis 
and Company announcement of neonatal chloramphenicol intox-
ication in 1959,(5) the recommended dose was 100 to 150mg 
per kilogram of body weight per day for children of 15 kilo-
grams or less.(6-9) 
It is the purpose of this paper to present not only 
the findings of the various investigators who made the in-
itial observations, but also the work of those who presented 
a physiologic explanation of the drug's toxicity when given 
to newborn and premature infants in excessive doses. 
1 
STATEMENT OF THE PROBLEM 
In 1959 workers in a number of newborn nurseries ob-
served an increase in toxic reactions and death rates, espe-
cially among premature infants, following the administration 
of this antibiotic.(10-14) These infants died in acute cir-
culatory collapse. 
In some instances sepsis was blamed for these deaths; 
however, no specific evidence of infection was found. Van 
Gelder (15) questioned sepsis as the cause of death because 
of the frequency of myocardial failure in these infants. 
Previous reports had not listed myocardial disease as a com-
mon feature of neonatal sepsis. Alltibiotic dosages were in-
creased and additional deaths resulted until the common eti-
ology was recognize~. Thereafter dosages were reduced and 
no more unexplained deaths occurred. Post mortem findings 
attributable to the use of chloramphenicol were absent in 
all organ systems including the hemat,opoietic system. 
Symptoms first appeared two to five days after contin-
ued therapy with chloramphenicol doses of 100 mg per kilogram 
per day or more. In many cases the symptoms appeared in the 
order of abdominal distention, with or without emesis, progres-
sive pallid cyanosis, vasomotor collapse, frequently accompaft 
nied by irregular respiration, and sometimes death within a few 
2 
hours after the onset of these symptoms. Th~s has been re-
ferred to ~n some ~nst~tut~ons as the "gray syndrome". The 
progress~on of symptoms from onset to death ~s accelerated 
with h~gher dose schedules. 
The delay in discover~ng the tox~c man~festations of 
chloramphen~col appears to be due to the fact that the drug 
was not used extensively in newborn infants prior to 1957 and 
the earl~er reports involved short-term therapy without tox-
~c~ty (16,17). Also, St. Geme po~nted out that the symptoms 
of chloramphen~col tox~c~ty are d~fficult to d~st~nguish from 
those of overwhelm~ng neonatal bacter~al and viral infections 
(18). 
This cl~nical picture, ~. e. acute circulatory col-
lapse, had been previously noted by European observers (19-21) 
~n adults and children following three to five days of high 
doses of chloramphenicol, but w~th few exceptions (9) th~s 
has been assoc~ated with therapy of sa1monella infect~ons. 
Vit~ ~n 1956 reported vasomotor collapse dur~ng the adminis-
tration of chloramphenicol in the absence of bact~rial in-
fect~on. He suggested that chloramphenicol had an adverse 
effect on carbohydrate metabol~smt hav~ng found fast~ng hypo-
glycemia in normal adults after five to ten days of oral ther-
apy and a return to normal ten days after the drug was d~scon-
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tinued. He was unable to determine the exact cause of this 
hypoglycemia but believed it involved a toxic action in the 
liver. The acute cardiovascular collapse was believed to 
be directly related to this hypoglycemic action. Groh (22) 
found delayed glucose breakdown in infants during chloram-
phenicol therapy. This delay was reversed when B vitamins 
were administered during treatment. He ascribed this delay 
to a decrease in B vitamin coenzymes in the G. I. tract. 
Patterson (23) observed anaphylactoid shock and vasomotor 
collapse during the administration of chloramphenicol. The 
patient developed pruritis thirty minutes following ingestion 
of the .first dose and in a few minutes developed angioneu-
rotic edema with laryngeal involvement. Blood pressure was 
unobtainable but treatment with epinephrine, theophylline, 
and diphenhydramine resulted in recovery in a few days. This 
reaction was also reported by Chatterjee (20) and Stephens 
(24) in 1950 and by Welch (25) in 1957 who observed typhoid 
fever deaths after initial improvement with chloramphenicol. 
This was considered to be a Jarisch-Herxheimer reaction from 
endotoxins released from destroyed virulent bacilli which 
overwhelmed the already weakened patient. Deaths in children 
under the age of three resulting from bacterial superinfection 
following chloramphenicol therapy have been mentio.ned (2). 
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These followed vomiting and diarrhea as a result of the su-
perinfection by resistent staphylococci. 
Substitution of the acid in the ester could produce 
an increased toxicity if the absorption rate was increased, 
(26) but this alone has had no qualitative effect on toxi-
city since similar deaths have been reported with the pal-
mitic acid and sodium succinate esters and the microcrys-
talline suspension. 
Studies were performed to determine if there exists 
any difference in the metabolic products of chloramphenicol 
in the serum and urine of newborn infants from those in the 
adult. Dill (27) found the nitro compounds to be identi-
cal to those in the adul,\,," He also discovered a new metab-
olite of chloramphenicol, a glycolic acid analogue, which 
possesses a low order of toxicity and is'unl~ely to have 
produced the side reactions seen in infants. 
Sutherland (10) considered methemoglobinemia because 
of the gray pallor. Although no determinations for methemo-
globin were done this possibility was discounted because of 
the absence of the characteristic slate cyanosis and choco-
late colored blood and tissue during life or at necropsy. 
Mongelli and Carrozzini (28) suggested that chloramphenicol 
has a primary toxic effect on the autonomic nervous system. 
The mechanism of action is unknown but there is con-
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$iderable evidenoe in the literature whioh suggests that the 
toxio manifestations of ohlorampheniool in infants are re-
lated to poor liver and kidney funotion. This reduced de-
toxication and exoretion leading to retention of the free drug 
results in toxio levels of 100 miorograms per milliliter 
after three days of oontinued therapy with high doses. 
REPORT OF CASES 
Two abstraoted cases will be presented to illustrate 
both the typical onset of symptoms and the insidious way in 
which this toxic effect manifests itself. 
CASE 1.(10) The patient was a 3,320 gm infant 
born of a Negro, married, Group A, Rh-positive, 
primipara with negative serologic test for syph-
ilis at 44 weeks' gestation. The mother had had 
no prenatal care and was admitted in labor with 
albuminuria and a systolic blood pressure over 
200 mm. Hg. 
After a five-and-one-half hour labor with 
no medication the infant was delivered by ver-
tex presentation under nitrous-oxide and oxygen 
anesthesia with a mediolateral episiotomy. At 
birth the infant had an Apgar score of 6 and 
was noted to be meconium stained. 
A foul odor was encountered on physical 
examination. The time of rupture of the ma-
ternal membranes was unknown, and 50,000 units 
of procaine penicillin and 250 mg of chloram-
phenicol were started intramuscularly every 
eight hours. Menadione sodium bisulfite 5 mg 
was given. At 8 hours the infant nursed at the 
breast. At 2 days rectal temperature was 99 F. 
The infant did not seem ill and he was circum-
cised. 
At 4 days of age the infant developed a 
gray oolor and a cold moist skin in spite of 
a temperature of 99 F. The infant died at 106 
hours of age, 8 hours after the onset of vascu-
6 
lar collapse. He received 250 mg of chloram-
phenicol 9 times in 72 hours, or 230 mg per 
kilogram per 24 hours. 
At postmortem examination the lungs 
~eighed 40 gmt and there was lobular consol-
idation. The heart weighed 21 gm and was 
moderately dilated. On microscopic examina-
tion there was patchy atelectasis and emphy-
sema without an apparent causative factor. 
There was a trivial pneumonitis. Quite ex-
tensive focal myocardial degeneration with 
pyknosis was seen. There was some vacuoliza-
tion of proximal renal tubules. No bone-mar-
row changes were noted. 
CASE II.(13) This 1,490 gram, Negro, female 
infant was born following a pregnancy which 
was complicated by vaginal bleeding during 
the third trimester. This was the fifth preg-
nancy for this 25-year-old mother with type 
no", Rh-positive blood, who had been in good 
health. A normal spontaneous delivery produced 
a small weak infant with poor respirations and 
a weak Moro response. There was no period of 
apnea. 
The infant was placed in an incubator 
in an atmosphere of high humidity and 35% oxy-
gen. The infant's vigor and strength improved 
and the oxygen was discontinued at the end of 
24 hOUTS. Color, cry and respirations were 
label.l&d tfgood tt by the attending nurses on 
repeated occasions, and there was no record 
of difficulty during the second day of life. 
At 24 hours of age, 5% glucose in water 
was given orally by means of a bottle and nip-
ple. This was repeated at 3-hour intervals on 
four occasions. A formula of milk was given 
at 36 hours of age and repeated every 3 hours. 
The first dose of chloramphenicol (93 mg) 
was given at 48 hours of age. At 62 hours of 
age, the infant's color was recorded as being 
ffd-q.skyU 'and oxygen was administered for 5 min-
utes. 
This type of episode occurred at 14 and 
16 hours, respectively, after the first and 
second doses of chloramphenicol. There followed 
a 12-hour period without difficulty, during 
which time the third and fourth doses of chlor-
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amphenicol were given. At 74 hours of age, 
the infant became cyanotic and the house 
physician was called. Oxygen was prescribed, 
with proper restrictions, and the chloram-
phenicol was continued. The infant ate well 
at the next feeding, but she became "very 
cyanotic" and her respirations were very ir-
regular and shallow. The milk formula was 
replaced with glucose in water which she took 
without difficulty for two feedings. 
At 84 hours of age (36 hours after the 
first dose of medication), she had a momentary 
period of apnea. However, she took the next 
four routine feedings without trouble, and her 
color and respirations were good; there were 
no reports of difficulty during this period. 
At 100 hours of age (52 hours after the first 
dose of chloramphenicol), respirations suddenly 
ceased and she could not be revived. Sf§) had 
received 560 mg Chloromycetin Palmitate 
divided in six doses during a period of 52 hours. 
The post-mortem examination showed ~a­
ture pulmonary structures. There were scattered 
areas of focal atelectasis. There was no lesion 
demonstrable which seemed to be of sufficient 
magnitude to be the cause of death. 
CLINICAL STUDY 
As a result of the increased mortality rates in 1958 
and 1959, following both prophylactic administration and 
treatment with chloramphenicol, several series of these unex-
plained deaths were collected. Burns et ale (7) studied four 
groups of premature infants treated after premature rupture 
of membranes. 
Group I received no antibiotic, group II received chlor-
amphenicol alone 100-165 mg per kilogram per day; group III 
received perdcillin 1.50,OOO-600,oOOu per day and streptomycin 
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, 
50 mg per k~logram per day. Group IV rece~ved all ant~bi-
ot~cs. 
The mortality rates of the groups g~ven chlorampheni-
col were markedly elevated from the other two groups. In-
terestingly, the mortality of the non-treated group wa~ 
~dentical to the pen~cill~n-streptomyc~n group. The infants 
treated with chloramphen~col followed a typ~cal cl~nioal 
course s~milar to that presented earlier. 
A retrospect~ve study by Lischner (22) et ale in March 
and Apr~l of 1958 ~cluded a search for the common et~ology 
in these deaths. There were common factors in n~ne of the 
ten ~nfants who died. Chloramphenicol in doses of over 113 mg 
per k~logram was g~ven early for prevention or treatment of 
infection. After two to five days of treatment initial im-
provement of symptoms was followed by vascular collapse and 
sudden death. Extensive m~crobiological studies had been car-
ried out by both bacteriolog~c cultures and v~rus isolation 
stud~es on HeLa cells, monkey kidney and l~ve animals. One 
of their 42 infants in this series had a single colony of 
Staphylococcus aureus and all the viral stud~es were negative. 
Post mortem exam~nation fa~led to reveal a cause of death. 
Van Gelder (15) et ale reported on two outbreaks of 
neonatal deaths but the associat~on w~th chloramphenicol did 
not become ev~dent unt~l the toxic~ty was announced by Parke, 
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Davis & Company. One of these deaths was in an infant 25 days 
of age. The maximum danger period for chloramphenicol toxic-
ityhas not been established t but Lischner indicates that 
infants three weeks and older can tolerate 200 mg per kilo-
gram per day provided they are not severely ill or dehydrated 
and further weakened by chloramphenicol therapy. The current 
recommended dosage by Parke t Davis, & Co. for premature and 
newborn infants is 25 mg per kilogram per day. Full term in-
fants may receive 25-50 mg per kilogram per day.(29) 
Only one case of the ttgray syndrome" has been reported 
in older infants. Morton (30) describe,s abdominal distention, 
progressive cyanosis, vasomotor collapse with irregular res-
piration and finally apnea in a six week old infant following 
a dosage of 750 mg intramuscularly in the first twelve hours, 
or 166 mg per kilogram. She asc,ribes the reason for toxicity 
at this age to anuria. 
Chloramphenicol toxicity has been extensively studied 
in animals.' The report of Kent (31) et ale illustrates the 
desirability of obtaining toxicity data on newborns as well 
as in the adult by their study on 394 newborn mice and two 
groups of adult mic,e. Their test animals received 230-2400 
mg per kilogram of chloramphenicol for five successive days 
and the contrql animals received 0.1 molar sodium succinate 
in 5% glucose. 
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The LD50 for newborn mioe in this experiment was 
315 ! 22.6 mg per kilogram per 24 hours and the LD50 for adult 
mioe was 1,675 Z 35.6 mg per kilogram per 24 hours. This is 
5.3 times the LD50 of newborns. 
Similar studies by Smith et ale showed the LD50 for 
adult mioe to be 245 mg per kilogram of body weight. They 
also were able to produoe a drop in bJ.ood pressure following 
intravenous doses of ohlorampheniool. With ~igh doses, fol-
lowing the fall in blood pressure, respiratory failure and 
death resulted.(32) 
BLOOD LEVEL STUDIES 
Following publioation of numerous reports in 1959, the 
Researoh Division of Parke, Davis and Company published a 
summary of the blood levels of different forms of ohloram-
phenicol in infants.(33) 
A oolorimetrio prooedure was used to determine the total 
nitro oompounds and aryl amines in the samples. This prooedure 
was desoribed by Glazko (34) in 1949 and is not speoifio for 
aotive ohloramphenicol sinoe the inactive degradation produots 
are inoluded in the determination. The method devised is 
based on reduction of the aromatic 'nitro group to a primary 
amine with titanous chloride or metallic zinc, followed by 
diazotization and coupling of the resulting amines. All re-
sults are expressed in chloramphenicol equivalents. 
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Determinations of the free and unconjugated portion of 
chloramphenicol provide data on the effective levels of chlor-
amphenicol and are performed by means of a turbidimetric pro-
cedure against Shigella sonnei.(32) This method is, however, 
less valuable than the colorimetric procedure for absorption 
and excretion studies. 
Chloramphenicol palmitate is a water insoluble ester 
which is absorbed slowly and poorly following hydrolysis in 
the intestine. An initial dose of 100 mg per kilogram and 
25 mg per kilogram per 6 hours is necessary to maintain a 
minimal therapeutic blood level of 10 micrograms per milli-
liter. (17) Following the control of particle,size"aatis-
factory blood levels oould be maintained with the reoommended 
doses. 
The series included infants under forty-eight hours of 
age and children ranging from one to twelve years of age. A 
single dose of 50 mg per kilogram was administered. The older 
age group obtained maximum blood levels in two hours and by 
four hours half of the maximum level remained. In the new-
born ,the maximum was reached in twelve hours indicating re-
duoed hydrolysis and absorption. The half-life was prolonged 
to twenty-eight hours. 
The microcrystalline form of chloramphenicol was de-
signed for intramuscular use. The slow rate of absorption 
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and rapid excretion produces low but prolonged blood levels. 
A single dose of 50 mg per kilogram was administered to 9 
infants under forty-eight hours of age. The maximum blood 
level with this form was reached in twenty-three hours. This 
was followed by a slow rate of fall and later by an acceler-
ation of the rate of removal which was believed due to either 
less absorption in the later periods or interval maturation 
of the infants hepatic and renal systems. 
This series showed that in most cases the infants one 
to four days of age had significantly higher blood levels 
than the infants that were fourteen to twenty-three days of 
age. 
Chloramphenicol sodium succinate is the preferred and 
only suitable parenteral form for intramuscular, intravenous, 
or subcutaneous use. Hydrolysis occurs in the tissues with 
\ 
liberation of free chloramphenicol. The study included 
children four to five years of age, infants ten to sixteen 
days of age and newborn infants one to two days of age. The 
dosage was 50 mg per kilogram except for the ten to sixteen 
day age group which received 25 mg per kilogram. 
High levels were obtained within a few hours in all 
groups indicating rapid absorption; however the half-life was 
twenty-six hours in the newborn group compared to ten hours 
in the second group and four hours for the older children. 
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The prolonged half-life in the newborn group indicates that 
elimination of the nitro compounds is slow. 
Chloramphenicol blood levels in newborns were studied by 
Wiltse (35) at the University of Nebraska Hospital. A total 
of 32 i:nfants was incorporated into this study and divided 
into groups according to weight. Infants weighing 2500 grams 
or less received 25 mg per kilogram per 24 hours and those 
weighing over 2500 grams received 50 mg per kilogram per 24 
hours. All infants received an initial loading dose of 50 mg 
per kilogram. Chloramphenicol succinate was given intramuscu-
larly in divided doses every 12 hours. 
Chemical assay of heparinized plasma samples was done 
by the colorimetric procedure of Glazko (34) et ale The re-
sulting blood levels were expressed in micrograms per milli-
liter o:f chloramphenicol equivalents which included total 
nitro compounds. 
One group included 19 infants and was divided into 4 
subgroups according to weights of the infants. All these in-
fants received only a single dose of 50 mg per kilogram"per 
7 milliliter,. Table I compares the half-lives of four weight 
ranges, i.e. 1000-2500 grams, 2500-3000 grams, 3000-3500 grams, 
and weights over 3500 grams. The half-lives were calculated 
from the 6-18 hour "K" value, on the assumption that first-
order kinetics apply_ A graph of the mean values of all 
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patients in table I is shown in figure 1. There appears to 
be a significant increase in the half-life with increasing 
weight of the infant as shown in figure 1. This may be due 
to increased amounts of adipose tissue in larger babies. 
Glazko (}6) found that chloramphenicol was widely distributed 
in all body tissues but did not i.nclude adipose tissue in his 
analysis. 
Table II represents another group of newborns divided 
into 2 subgroups according to weight. Plasma levels were ob-
tained on samples drawn 6 hours after the first dose on days 
1, 3, and 5, i.e. at 6, 54, and 102 hours. 
The mean values for the larger infant group are approxi-
mately twice those of the smaller group indicating that full 
term babies probably do not eliminate the antibiotic any more 
satisfactorily than the prematures. This suggests that in-
cre~sing the dose in infants weighing 2500 grams or more is 
not justified and can even be dangerouse Sutherland (37) re-
cently recommended doses of 25 mg per kilogram per 24 hours 
for premature and full term infants under one week of age and 
50 mg per kilogram per 24 hours for all infants over one week 
of age. Day 3 is the most significant with two blood levels 
within the toxic range. Both of these infants were large 
babies well over 2500 grams. Lowering the dose schedules 
below 25 mg per kilogram per 24 hours would result in inef-
15 
fectiveblood levels of 10 micrograms per milliliter or less 
in some cases. In this series one sample was below 10 micro-
grams a't the 25 mg per kilogram per 24 hours dosage. 
The wide standard deviation indicates that toxic levels 
can be reached with these doses in some cases, thus use of 
this antibiotic in newborn infants requires closely monitored 
blood levels to assure safe administration. 
16 
TABLE I. Chloramph.enicol Half-lives in Newborn Infants 
Patient Birth Weight 6-18 hr. "k" Half-life 
number (kg) (hrs.) 
1 1.984 15.4 10.7 
2 1.210 21.1 14.6 
3 1.990 21.9 15.2 
4 2.168 22.9 1:2&2 
1.838 Mean 14.1 
SDj;,2.6 
5 2.533 27.6 19.1 
6 2.573 21.4 14.8 
7 2.520 21.8 1ge1 
2.542 Mean 1.3 
SDj;,204 
8 3.020 33.7 23.4 
9 3.160 23.5 16.3 
10 30225 24.8 17 .. 2 
11 3.422 26.1 18.1 
12 3.290 41.9 29.0 
13 3.232 26.2 1802 
14 3.223 16 .. 1 11.2 
3.225 Mean 19.1 
SDV·7 
15 3.500 25.5 17.7 
16 3.512 22.4 15.5 
17 3.561 43.3 30.0 
18 3.885 37.0 25.6 
19 4.104 26.0 18.0 































Time in Hours 
A = Mean half-lives of total nitro compounds for infants 
6-18 hours after intramuscular administration of chloram-
phenicol succinate in a single dose of 50 mg per kilogram. 
B = Variations to 1 standard deviation. 
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TABLE II. Chloramphenicol Plasma Levels (micrograms per milli-
liter) in Newborn Infants following Doses of 25mg/kg/24hrs. in 
Group I. and 50mg/kg/24hrs. in Group II. 
-Weight Dosage Day 1 Day 3 Day 5 
(kg) mg/kg/24hrs. (6 hra.) (54 hrs.) (102 hrs.) 
Group I 
1.707 23.4 29.5 37.7 16.7 
2.205 22.7 29.0 24.5 4.7 
2.290 21.8 17.1 34.2 51.3 
2.245 26.7 12.0 22·Z 2t·l Mean 23.8 Mean 32.3 Mean 2.4 
SD.±,6.3 SD.±,5.8 SD.±,20.2 
Group II 
2.760 50.7 57.8 59 .. 0 
2.915 51.5 28.1 26.3 25.4 
3.130 47.9 76.8 66.8 43.1 
3.133 51.1 72.5 128.9 64.6 
3.225 49.6 50.7 58.1 36.5 
3.339 50.9 57.1 99.3 46.6 
3.390 50.1 46.3 40.8 
3.740 48.1 20.2 25.3 20.2 
4.907 48.9 28•1 21 •1 24•0 
Mean 51.9 Mean 62.2 Mean 43.4 
SD.±,19. 6 SD.±,33.3 SD.±,14.7 
---=~--------~-
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FIGURE 2a. Chloramphenicol plasma levels for infants 
weighing less than 2500 grams following repeated injections 
of chloramphenicol succinate in doses of 25 mg per kilo-
gram per 24 hours. Dotted lines represent variations to 1 
standard deviation. 
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FIGURE 2b. Chloramphenicol plasma levels for infants 
weighing more.than 2500 grams following repeated injections 
of chloramphenicol succinate in doses of 50 mg per kilo-
gram per 24 hours. Dotted lines represent variations to 1 
standard deviation. 
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METABOLIC DISPOSITION OF CHLORAMPHENICOL 
It is apparent that several functions are quantitatively 
less well developed in the infant as compared to the adult. 
These include reduced glomerular filtration and tubular se-
cretion as well as a number of enzymatic reactions. Glazko 
et ale (38) reported that chloramphenicol was inactivated 
through conjugation with glucuronic acid. Brown and Zuelzer 
(39,40) later showed that the fetal liver at mid-gestation 
posseses no glucuronide conjugating activity. The newborn 
liver has about one-half the activity of the adult. but by 
15-20 days of life the enzyme systems are comparable to the 
adult. They speculated that this inability to form glucuron-
ide may have resulted in the formation of an alternate and 
more toxic metabolic product. 
The deficiency in the newborn liver involved two en-
zymatic steps of the glucuronide conjugation pathway. (41) 
Uridine diphosphate glucuronic dehydrogenase and glururonyl 
transferase were deficient resulting ~n absence of the uri dine 
diphosphoglucuronic acid (UDPGA). The UDPGA, combining with 
the agent to be detoxified (bilirubin in these experiments), 
results,~n the bilirubin glucuronide, or the direct reacting 
bilirubin. 
Billing (42) demonstrated that the capacity to conjugate 
bilirubin with glucuronic acid is not entirely confined to the 
21 
liver and suggested that the formation of the monoglucuronide 
may be' effected in the kidney. In vitro studies showed that 
the kidney has as high as one-fourth the conjugating activity 
of the liver. 
The amount of a dose of chloramphenicol recovered in 
twenty-four-hour urine approaches 90% in the adult human. 
Only 5-15% of this is microbiologically active or free chlor-
amphenicol and about 90% is excreted as inactive nitro com-
pounds, mainly the glucuronide. The remainder of the dose 
excreted includes a small amount of products of hydrolysis, 
less than 3% excreted as aryl amines into the bile, and less 
than 1% excreted into the feces a~ aryl nitro and amine de-
rivatives.(43) These mechanisms of degredation of the chlor-
amphenicol molecule occur at the sites illustrated: 
°2N 




~ NfCO-CHC12 , 
C-C-CH OH 
H H 2 
\ glucuronide 
linkage 
To determine the potential toxicity of chloramphenicol 
and its metabolic products, the glucuronide was given in large 
amounts to rats without side effects.(44) Indirect studies 
on other metabolites also failed to produce toxicity (27,43) 
22 
indicating that the toxicity of chloramphenicol in newborns 
was probably due to the free antibiotic. 
In infants the amount of free chloramphenicol excreted 
in the urine is similarly 5-10% but the excretion of the 
glucuronide is considerably less than normal (50% of the 
dose). There is also a higher proportion of the glucuronide 
in the blood of newborns in addition to high, prolonged levels 
of free chloramphenicol. This appears to be the result of 
both poor renal function and a deficient glucuronide conju-
gating system. 
Analogous studies to those in the newborn were per-
formed on adult patients with hepatic cirrhosis which re-
vealed that the half-life for active chloramphenicol was 
markedly prolonged. However, the defect was in the rate of 
conversion to the glucuronide not the total amount converted. 
In patients with acute renal failure the half-life for active 
chloramphenicol was not prolonged but high levels of the chlor-
amphenicol glucuronide were found in the blood. No toxicity 
occurred. This prolonged serum half-life and accumulation of 
metabolic products in these anuric patients indicates that 
removal other than by renal mechanisms is slow (less than 1% 
per hour).(43) The glucuronide conjugate is excreted by renal 
tubular secretion while the free drug is excreted by glomer-
ular filtration.(36) 
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Experimental work with creatinine excretion suggests 
that the tubules of newborn infants have not yet developed 
the ability to excrete this substance.(45) Driscoll reported 
infant glomerular filtration rates for inulin, mannitol and 
creatinine to be 30 to 50 per cent of adult levels. The clear-
ances of para-aminohippurate and iodopyrcet were 20 to 40 per 
cent those in the adult.(46) 
DISCUSSION 
Following the numerous reports of the Ilgray syndrome lf 
in 1951 to 1959. the physiologic explanation of chlorampheni-
col~toxicity was based on the excessive doses used between 
1951 and 1959 together with reduced glucuronide conjugation 
and impaired renal excretion. This resulted in toxic blood 
levels above 100 micrograms per milliliter. This potential 
toxicity was an important consideration until the infant be-
came approximately three weeks of age. The conclusions of 
these authors were that the free drug was the toxic component, 
and although the mechanism of action was unknown, the toxic 
reactions were related to the impaired glucuronide conjugation 
and impaired renal excretion. 
These conclusions do not satisfy the question why the 
excessive concentration of the chloramphenicol molecule re-
sults in the clinical picture of cardiovascular collapse. 
Further research in the literature revealed that Japanese 
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writers in 1952 studied the effects of various antibiotics on 
blood pressure and respiration in the rabbit.(47) Chloram-
phenicol was the most potent drug. Large doses produced 
slight to moderate decreases in blood pressure, bradycardia, 
and decreased amplitude of respiration which did not parallel 
the dosages used. The blood pressure drop was believed to be 
peripheral in origin and chiefly responsible for the cardiac 
action. They also noted that chloramphenicol in concentration 
of 1:5000 to 1:4000 stimulated a segment of frog intestine 
but in concentrations of 1:10,000 produced inhibition only. 
Swain (48) also found chloramphenicol the most potent 
cardiac depressant as compared with other antibiotics. Using 
a dog heart-lung preparation he induced heart failure with a 
100 t.o 200 mg dose of chloramphenicol. The failure was slowly 
reversed by ouabain and promptly reversed by 100 mg of calcium 
chloride. Successive episodes of heart failure required 
smaller and smaller doses of chloramphenicol and progressively 
larger doses of calcium chloride to reverse it. The drug's 
cardiac depressant actions were found to be indistinguishable 
from pentobarbital, and on a molar basis chloramphenicol was 
more potent. 
A technique for titrating calcium ions was developed to 
determine if the agents bound the ion. By this method Swain 
concluded that chloramphenicol acted by removing ionized cal-
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cium from the environment of the heart rather than binding 
the ca1cium ion, because ca1cium ch10ride wou1d not comp1ete1y 
reverse severa1 consecutive episodes of heart fai1ure. A1-
though the experiment is significant, his conc1usions do not 
consider that there may be other mechanisms for the cardiac 
.fai1ure. 
Kretchmer specu1ated that the toxicity in infants cou1d 
be exp1ained by the action of ch10ramphenic01 on protein syn-
thesis. (49) Ch10ramphenic01 is a se1ective inhibitor of pro-
tein synthesis. The RNA formed in the presence of ch10ram-
phenic01 is abnorma1 being unstab1e fo110wing the drugs re-
mova1. The hypothesis is that ch10ramphenic01 b10cks the 
conversion of the'unstab1e RNA polymer to a stab1e ribonucleo-
protein. (50) 
Roblin (51) has shown that the antibacterial action of 
smal1 concentrations of chloramphenicol toward Escherchia 
coli is reversed by phenylalanine which has a simi1ar struc~ 
ture. This appears to be a non-competitive inhibition between 
the chloramphenicol and phenyla1anine molecules • 





Although antibiotics are not generally believed to 
function as metabolic antagonists, it could be speculated 
that the chloramphenicol molecule might have an inhibitory 
effect on the synthesis of catecholamines since tyrosine, the 
initial step in the pathway to epinephrine, is formed from 
phenylalanine. The structures of chloramphenicol and epi-





HO ~ CHOHCH2 
HOi""--........ .., 
epinephrine 
This possibility seems more likely as a cause for car-
diovascular collapse when it is recalled that the opposite 
effects of catecholamines were obtained with the heart-lung 
preparation, frog intestine and rabbit experiments. Disturbed 
carbohydrate metabolism with fasting hypoglycemia was noted 
as well as the clinical course of the infants affected. 
SUMMARY 
Chloramphenicol toxicity in the newborn, Le. the Ugray 
syndrome tf is described and the findings of the various workers 
are presented. Two case reports describe the typical onset 
of symptoms and the insidious way in which this toxicity mani-
fests itself. 
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As a result of the increased mortality rates in newborn 
nurseries several series of these deaths were collected and 
animal studies were obtained to compare the tolerance of new-
born animals to adult animals. 
Blood level studies by Parke, Davis and Company are 
presented and the different forms of the antibiotic are con-
sidered. Additional unpublished data on chloramphenicol suc-
cinate is also presented. 
Emphasis is placed on the metabolic disposition of chlor-
amphenicol because of the development of hepatic and renal 
function in the infant. 
Because the data obtained did not adequately explain why 
cardiovascular collapse occurred in these infants, a discus-
sion of the effects of chloramphenicol an the cardiovascular 
system and speculation of the possible mechanisms involved are 
presented. 
CONCLUSIONS 
Chloramphenicol is toxic to premature infants and new-
borns up to three weeks of age when blood levels exceed 100 
micrograms per milliliter. This toxicity is manifested by 
circulatory collapse and termed the "gray syndrome fl • Effec-
tive blood levels of 10 micrograms per milliliter are usually 
obtained with doses of 25 mg per kilogram per day for premature 
and newborn infants. Full term infants may receive from 25 to 
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50 mg per kilogram per day, but the data suggests that full 
term infants probably do not handle the drug any more effec-
tively than the prematures. Most of the deaths occurred fol-
lowing doses of 100 to 150 mg per kilogram per day, although 
the experiments show that toxic levels may be reached with 
50 mg per kilogram. 
The mechanism of this toxicity is unknown but the evi-
dence in the literature indicates that it is related to re-
duced detoxication by the glucuronide conjugation pathway and 
poor renal excretion resulting in abnormally high blood levels 
/ 
of the free antibiotic. 
An attempt to explain why this toxicity is manifested 
by cardiovascular collapse resulted in speculation by several 
authors. Chloramphenicol produced a decrease in blood pressure 
and respiration in rabbits which was thought to be peripheral 
in origin. It produced cardiac failure in a dog heart-lung 
preparation which was thought to occur as a result of a de-
crease in calcium ion available to the myocardium. 
There is some evidence that chloramphenicol and phenyl-
alanine are antagonistic in biological systems. Speculation 
along these lines includes the possiQility that chloramphenicol 
may exert some antagonism to the synthesis of catecholamines 
in the pathway from phenylalanine to epinephrine. This hy-
pothesis could perhaps be supported with animal experiments 
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which include the determination of urinary catecholamines 
during chloramphenicol administration. There is no indication 
in the literature that this has been done.(52) Further work 
utilizing data from Swain's experiments may aid in identifying 
the cause of the "gray syndrome". 
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